MariTide vs Semaglutide: Monthly Antibody-Peptide Conjugate vs Weekly GLP-1

Introduction#

MariTide (maridebart cafraglutide) and semaglutide represent fundamentally different approaches to incretin-based obesity therapy. Semaglutide is the most widely prescribed GLP-1 agonist, with an extensive evidence base spanning diabetes, obesity, and cardiovascular outcomes. MariTide, developed by Amgen, is a first-in-class antibody-peptide conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism in a single molecule designed for once-monthly dosing.

This comparison is noteworthy not just for the efficacy data, but for the strategic divergence in mechanism: while tirzepatide and other dual agonists activate the GIP receptor alongside GLP-1R, MariTide takes the opposite approach by blocking GIPR while activating GLP-1R. Both strategies appear to enhance weight loss beyond GLP-1 agonism alone, raising fundamental questions about GIP receptor biology in obesity.

Mechanism of Action Comparison#

MariTide#

MariTide is a bispecific antibody-peptide conjugate (APC) consisting of a fully human monoclonal antibody that antagonizes the GIP receptor (GIPR), conjugated to two GLP-1 receptor agonist peptide molecules via amino acid linkers. This design enables three distinct pharmacological actions in a single molecule:

1. GLP-1 receptor agonism: The two conjugated GLP-1 analog peptides activate GLP-1R to produce appetite suppression, glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying
2. GIP receptor antagonism: The antibody component blocks GIP signaling, which may reduce fat storage and modify energy metabolism
3. Extended half-life: The antibody backbone provides a half-life of approximately 21 days -- three times longer than any approved weekly incretin therapy -- enabling once-monthly dosing

The GIP antagonism approach is the most distinctive feature. While tirzepatide enhances GIP signaling (agonism) to produce metabolic benefits, MariTide blocks GIP signaling (antagonism). The fact that both approaches appear to enhance weight loss beyond GLP-1 agonism alone suggests that modulating GIP activity in either direction may be beneficial, potentially through different downstream mechanisms.

Semaglutide#

Semaglutide is a selective GLP-1 receptor agonist -- a synthetic analog of human GLP-1(7-37) with an Aib substitution at position 8 for DPP-4 resistance and a C18 fatty diacid chain at lysine-26 for albumin binding. The half-life is approximately 7 days, enabling once-weekly injection.

GLP-1R activation produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction through hypothalamic and brainstem signaling. The oral formulation (Rybelsus) uses a sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) absorption enhancer for oral bioavailability.

Mechanistic Comparison#

Dosing Comparison#

MariTide Dosing#

MariTide is administered as a once-monthly subcutaneous injection -- the longest dosing interval of any obesity medication in development. The phase 2 trial tested multiple dose levels over 52 weeks. The ~21-day half-life means patients require only 12 injections per year compared to 52 with weekly therapies.

Phase 3 dose selection has not been publicly announced.

Semaglutide Dosing#

• Wegovy (obesity): 0.25 mg weekly escalating over 16 weeks to the target dose of 2.4 mg
• Ozempic (T2D): 0.25 mg weekly escalating to 0.5, 1, or 2 mg
• Rybelsus (oral): 3 mg daily escalating to 7 or 14 mg

Dosing Comparison Table#

Side Effects Comparison#

MariTide Side Effects#

The phase 2 trial showed that the most common adverse events with MariTide were GI-related, including nausea, vomiting, and constipation. A distinctive finding was that nausea and vomiting were predominantly mild, transient, and primarily associated with the first dose. This pattern is potentially significant because it suggests that GI tolerability improves substantially after the initial injection, unlike weekly incretins where GI effects tend to recur with each dose escalation.

Improvements in cardiometabolic markers including waist circumference, blood pressure, hs-CRP, and lipid parameters were also observed.

Semaglutide Side Effects#

Semaglutide's GI profile is well characterized. Nausea 15-44%, vomiting 5-24%, diarrhea 8-30%, constipation 5-24%. Rates are higher at the 2.4 mg weight management dose. Most effects are mild to moderate and diminish with continued treatment but can recur during dose escalation. Additional known effects include cholelithiasis, modest heart rate increase of 2-4 bpm, and a boxed warning for thyroid C-cell tumors.

Safety Comparison Table#

Research Evidence Comparison#

MariTide Research#

MariTide's key evidence comes from a phase 2 trial published in the New England Journal of Medicine (2025):

• Design: 592 participants across two cohorts -- obesity without T2D, and obesity with T2D -- over 52 weeks
• Obesity cohort: Mean weight loss ranged from -12.3% to -16.2% with MariTide vs -2.5% with placebo (up to 20% in some analyses)
• Obesity + T2D cohort: Mean weight loss ranged from -8.4% to -12.3% with MariTide vs -1.7% with placebo; HbA1c reductions up to 1.6 percentage points
• Weight trajectory: Weight loss had not plateaued by 52 weeks, indicating potential for further reduction with continued treatment
• Cardiometabolic: Improvements in waist circumference, blood pressure, hs-CRP, and lipid parameters

Evidence level: Moderate -- well-designed phase 2 with NEJM publication, but single trial, no head-to-head comparisons.

Semaglutide Research#

• SUSTAIN (T2D): Seven trials, >4,000 patients, HbA1c 1.2-2.2%
• PIONEER (oral T2D): Nine trials, >9,000 patients
• STEP (obesity): STEP 1 showed 14.9% at 68 weeks; STEP 5 confirmed 15.2% at 2 years
• SELECT (CV outcomes): 17,604 patients, 20% MACE reduction

Evidence level: Very high -- extensive multi-program evidence with cardiovascular outcomes.

Key Differences Summary#

• Drug platform: MariTide is a large antibody-peptide conjugate (~150 kDa). Semaglutide is a small peptide (~4 kDa). This structural difference enables MariTide's monthly dosing but prevents oral formulation.
• GIP receptor approach: MariTide blocks GIPR (antagonism). Semaglutide does not interact with GIPR. Tirzepatide activates GIPR (agonism). All three approaches produce weight loss, raising questions about GIP biology.
• Dosing frequency: MariTide monthly (12/year) vs semaglutide weekly (52/year). This is the most practical differentiator for patients.
• GI tolerability pattern: MariTide's GI side effects appear concentrated at the first dose, while semaglutide's recur with dose escalation. If confirmed in phase 3, this could meaningfully improve patient experience.
• Weight loss: MariTide showed up to 20% at 52 weeks (phase 2, no plateau). Semaglutide showed 14.9% at 68 weeks (phase 3, STEP 1). Different study phases limit direct comparison.
• CV outcomes: Semaglutide has proven benefit (SELECT). MariTide has none.
• Formulation flexibility: Semaglutide offers oral and injectable options. MariTide's antibody structure limits it to injectable delivery.

Conclusion#

MariTide and semaglutide represent two fundamentally different therapeutic modalities applied to the same disease. Semaglutide is the established standard of care with unmatched evidence breadth, proven cardiovascular benefit, and the flexibility of injectable and oral formulations. For any patient requiring treatment today, semaglutide remains the evidence-based choice.

MariTide's differentiation is compelling on multiple fronts. Once-monthly dosing could dramatically improve adherence -- a major barrier in chronic weight management. The GIP receptor antagonism represents a genuinely novel mechanism that has produced competitive weight loss results. The observation that GI side effects concentrate at the first dose (rather than recurring with each injection) could improve the patient experience if confirmed in larger trials.

The critical unanswered questions are whether MariTide's phase 2 results will replicate in phase 3, whether the GIP antagonism approach provides unique metabolic benefits (such as lean mass preservation) beyond weight loss, and whether the antibody-peptide conjugate format introduces any long-term immunogenicity concerns. Phase 3 trials will need to address all of these questions before MariTide can challenge semaglutide's market position.

Further Reading#

• MariTide Overview and Research Guide
• MariTide Side Effects
• MariTide Dosing Protocols
• Semaglutide Overview and Research Guide
• Semaglutide Side Effects
• Semaglutide Dosing Protocols